New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately 10% of tumors show primary resistance, whereas acquired resistance appears to be an almost ubiquitous occurrence, leading to treatment failure. The identification of differentially expressed genes or genomic mutational signatures able to predict sensitivity or resistance to CDK4/6 inhibitors is critical for medical decision making and for avoiding or counteracting primary or acquired resistance against CDK4/6 inhibitors. In this review, we summarize the main mechanisms of resistance to CDK4/6 inhibitors, focusing on those associated with potentially relevant biomarkers that could predict patients’ response/resistance to treatment. Recent advances in biomarker identification are discussed, including the potential use of liquid biopsy for BC management and the role of multiple microRNAs as molecular predictors of cancer cell sensitivity and resistance to CDK4/6 inhibitors.

Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration / Krasniqi, Eriseld; Goeman, Frauke; Pulito, Claudio; Palcau, Alina Catalina; Ciuffreda, Ludovica; Di Lisa, Francesca Sofia; Filomeno, Lorena; Barba, Maddalena; Pizzuti, Laura; Cappuzzo, Federico; Sanguineti, Giuseppe; Maugeri-Saccà, Marcello; Ciliberto, Gennaro; Fanciulli, Maurizio; Blandino, Giovanni; Vici, Patrizia. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 23:23(2022). [10.3390/ijms232314534]

Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration

Goeman, Frauke;Pulito, Claudio
;
Palcau, Alina Catalina;Di Lisa, Francesca Sofia;Barba, Maddalena
;
Pizzuti, Laura;Fanciulli, Maurizio;
2022

Abstract

New evidence on the impact of dysregulation of the CDK4/6 pathway on breast cancer (BC) cell proliferation has led to the development of selective CDK4/6 inhibitors, which have radically changed the management of advanced BC. Despite the improved outcomes obtained by CDK4/6 inhibitors, approximately 10% of tumors show primary resistance, whereas acquired resistance appears to be an almost ubiquitous occurrence, leading to treatment failure. The identification of differentially expressed genes or genomic mutational signatures able to predict sensitivity or resistance to CDK4/6 inhibitors is critical for medical decision making and for avoiding or counteracting primary or acquired resistance against CDK4/6 inhibitors. In this review, we summarize the main mechanisms of resistance to CDK4/6 inhibitors, focusing on those associated with potentially relevant biomarkers that could predict patients’ response/resistance to treatment. Recent advances in biomarker identification are discussed, including the potential use of liquid biopsy for BC management and the role of multiple microRNAs as molecular predictors of cancer cell sensitivity and resistance to CDK4/6 inhibitors.
2022
breast cancer; CDK4/6 inhibitors; liquid biopsy; microRNA; palbociclib; abemaciclib; ribociclib
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Biomarkers of response and resistance to CDK4/6 inhibitors in breast cancer: hints from liquid biopsy and microRNA exploration / Krasniqi, Eriseld; Goeman, Frauke; Pulito, Claudio; Palcau, Alina Catalina; Ciuffreda, Ludovica; Di Lisa, Francesca Sofia; Filomeno, Lorena; Barba, Maddalena; Pizzuti, Laura; Cappuzzo, Federico; Sanguineti, Giuseppe; Maugeri-Saccà, Marcello; Ciliberto, Gennaro; Fanciulli, Maurizio; Blandino, Giovanni; Vici, Patrizia. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 23:23(2022). [10.3390/ijms232314534]
File allegati a questo prodotto
File Dimensione Formato  
Krasniqi_Biomarkers_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 932.86 kB
Formato Adobe PDF
932.86 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1662477
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 2
social impact